You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

Citation Tools

Article menu

This article has a correction. Please see:

Global health
Original research
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Mohraz M, Salehi M, Tabarsi P, et al
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
BMJ Open 2022;12:e056872. doi: 10.1136/bmjopen-2021-056872